An LSD-Based Depression Drug Just Passed a Phase 3 Trial. Here's What That Actually Means for You.

On June 22, 2026, Definium Therapeutics (Nasdaq: DFTX, the company formerly known as MindMed) announced that its lead candidate — an LSD-based dissolving tablet called DT120 — succeeded in its first pivotal depression trial. For anyone who has watched psychedelic medicine inch toward the mainstream, it's a genuine milestone: the first time an LSD-derived therapy has cleared a Phase 3 study for major depression.

It's also widely misunderstood. A positive Phase 3 trial is not an approved drug, and an approved drug is not the same as one you can get. If you're living with depression right now, the most useful thing this news can do is clarify what is — and isn't — available to you today.

Here's the honest version.

What the trial actually showed

The study, called Emerge, tested a single 100-microgram dose of DT120 against a placebo in 149 adults with major depressive disorder, measured on the MADRS depression scale.

The results were strong. At Week 6, the DT120 group improved by 8.1 points more than placebo on MADRS — a difference the company reported as highly statistically significant. Roughly a quarter of patients on DT120 (24%) were in remission at Week 6, compared with 3% on placebo. The treatment was generally well tolerated: the company reported no serious adverse events and no suicidality signal, with side effects that were mostly mild to moderate and concentrated on the dosing day itself.

Those are good numbers from a single, well-designed trial. They are also topline numbers — a company press release, not yet peer-reviewed, full-dataset, or reviewed by the FDA. That distinction matters for everything that follows.

Why "passed Phase 3" doesn't mean "available soon"

It's tempting to read a positive Phase 3 as the finish line. It isn't — and for a drug like this, several large gates remain.

One trial usually isn't enough. For an FDA approval, a drug typically needs two positive pivotal trials per condition. Emerge is the first MDD trial; a second, called Ascend, is still enrolling and has not yet reported.

LSD is still a Schedule I drug. This is the part most coverage skips. DT120's active ingredient is a form of LSD, which federal law currently classifies as having no accepted medical use. Even if the FDA approves DT120, the Drug Enforcement Administration would then have to reschedule it before it could be legally prescribed — an obligation Definium itself flags as a step that must happen before any approved product containing a Schedule I substance can be legally marketed. That's additional regulatory time beyond approval itself.

The company hasn't announced a filing date. Definium has not announced a specific date for submitting DT120 to the FDA for approval, and its own disclosures list that timing as undetermined. Realistically, even in an optimistic scenario, this points to availability no earlier than 2027–2028 — and likely later for depression specifically.

So: real progress, real milestone, but not a treatment you'll be picking up at a pharmacy in the foreseeable future.

How this drug would actually be used

There's another reason DT120 won't work like a typical antidepressant: you don't take it home.

In the Emerge trial, the dose was given once, in a clinic, under supervision — and the monitored session ran long. On dosing day, patients were assessed for readiness to leave starting around hour five, with an average of about 5.8 hours before they met the trial's end-of-session checklist. The company has said it expects an approved version to be delivered the same way, almost certainly under a restricted distribution program where only certified clinics can administer it.

There's a real-world precedent for this: Spravato (esketamine), an FDA-approved depression treatment that can only be given in certified settings under direct monitoring, with patients observed for at least two hours and unable to drive themselves home. DT120's much longer session would make that model even more demanding — pointing toward a limited number of specialized psychiatric clinics, not retail pharmacies or take-home prescriptions.

In other words, when DT120 eventually arrives, where you can get it will matter as much as whether it's approved.

What you can actually access today

If you're dealing with treatment-resistant depression now, the meaningful question isn't DT120 — it's what's legally available in 2026. Here's the current landscape, described plainly:

Ketamine, off-label and nationwide. Generic ketamine is FDA-approved as an anesthetic, and physicians may legally use it off-label for depression. It's available through clinics across the country. Because there's no FDA approval for mood disorders, protocols vary between clinics, it's generally not covered by insurance, and quality and pricing differ widely — which is precisely why verified information about individual clinics matters. You can browse verified ketamine clinics in our directory by state to compare clinical oversight, protocols, and pricing.

Spravato (esketamine), FDA-approved for treatment-resistant depression. This is a true FDA-approved prescription product, delivered as a nasal spray in a certified clinical setting under monitoring. It's sometimes covered by insurance. It's the closest thing to an "approved psychedelic-adjacent" depression treatment that exists today.

State-regulated psilocybin, in Oregon and Colorado only. Both states run licensed, supervised psilocybin programs for adults 21+. Importantly, these are state-licensed, facilitator-supervised supported-use frameworks — not a prescription or medical-treatment model. There's no prescription, no diagnosis required, facilitators aren't necessarily clinicians, it's paid out of pocket, and it remains illegal under federal law. It exists in those two states and nowhere else.

DT120 / LSD: clinical trials only. Outside of enrolling in one of Definium's studies, there is no legal way to access DT120 in the United States. It can't be prescribed, and it isn't part of any state program.

The bottom line

The Emerge readout is a real step forward for psychedelic medicine, and worth paying attention to. But it changes very little about your options this year. DT120 is years from a pharmacy, gated behind a second trial, an FDA decision, and a DEA rescheduling — and even then, it will be a clinic-administered treatment available at a limited set of certified sites.

If you're looking for help with depression today, the realistic conversation is about ketamine, Spravato, and — in two states — supervised psilocybin. The future Definium is building toward is promising. It just isn't here yet.

---

This article is for general informational purposes and is not medical advice. Treatment decisions should be made with a qualified healthcare provider. Clinical trial figures cited are company-reported topline results as of June 2026 and have not yet been peer-reviewed or reviewed by the FDA.